Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate

National Asthma Education and Prevention Program, 1997 Derendorf, 1998, Pharmacokinetics and pharmacodynamics of inhaled corticosteroids, J Allergy Clin Immunol., 101, S440, 10.1016/S0091-6749(98)70156-3 Kelly, 1998, Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/ pharmacodynamic comparison of the inhaled corticosteroids, J Allergy Clin Immunol., 102, S36, 10.1016/S0091-6749(98)70004-1 Derendorf, 1997, Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety, Respir Med., 91, 22, 10.1016/S0954-6111(97)90102-5 National Institutes of Health, National Heart, Lung, and Blood Institute, 1995, Global Initiative for Asthma Barnes, 1998, Efficacy and safety of inhaled corticosteroids. New developments, Am J Respir Crit Care Med., 157, S1, 10.1164/ajrccm.157.3.157315 Toogood, 1998, Inhaled steroid asthma treatment: ‘Primum non nocere’, Can Respir J., 5, 50A Barnes, 1995, Inhaled glucocorticoids for asthma, N Engl J Med., 332, 868, 10.1056/NEJM199503303321307 Williamson, 1995, Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations, Eur Respir J., 8, 590, 10.1183/09031936.95.08040590 Lipworth, 1997, Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids, Thorax, 52, 476, 10.1136/thx.52.5.476 Wolthers, 1999, Measures of hypothalamicpituitary-ad renal function in patients with asthma treated with inhaled glucocorticoids: Clinical and researchimplications, J Asthma., 36, 477, 10.3109/02770909909054553 Pescollderungg, 2003, Systemic activity of inhaled corticosteroid treatment in asthmatic children: Corticotrophin releasing hormone test, Thorax, 58, 227, 10.1136/thorax.58.3.227 Nelson, 2002, A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma patients treated with inhaled corticosteroids, J Clin Pharmacol., 42, 319, 10.1177/00912700222011355 Crowley, 2003, Inhaled glucocorticoids and adrenal function: An update, Paediatr Respir Rev., 4, 153, 10.1016/S1526-0542(03)00029-0 Thaler, 1998, The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency, J Clin Endocrinol Metab., 83, 2726, 10.1210/jc.83.8.2726 Abdu, 1999, Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance testfor assessment of the hypothalamopituitary-adrenal axis in patients with pituitary disease, J Clin Endocrinol Metab., 84, 838, 10.1210/jc.84.3.838 Broide, 1995, Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids, J Clin Endocrinol Metab., 80, 1243, 10.1210/jc.80.4.1243 Orth, 1992, The adrenal cortex, 489 Allen, 2003, Inhaled corticosteroids: Past lessons and future issues, J Allergy Clin Immunol, 112, S1, 10.1016/S0091-6749(03)01859-1 Todd, 2002, Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom, Arch Dis Child., 87, 457, 10.1136/adc.87.6.457 Drake, 2002, Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate, BMJ, 324, 1081, 10.1136/bmj.324.7345.1081 Dunlop, 2002, Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid, Pediatr Pulmonol., 34, 85, 10.1002/ppul.10132 Konig, 1993, Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate, J Pediatr, 122, 219, 10.1016/S0022-3476(06)80116-2 Ali, 1991, Bone turnover during high dose inhaled corticosteroid treatment, Thorax, 46, 160, 10.1136/thx.46.3.160 Hanania, 1995, Dose-related decrease in bone density among asth matic patients treated with inhaled corticosteroids, J Allergy Clin Immunol., 96, 571, 10.1016/S0091-6749(95)70254-7 Sivri, 2001, Effect of the longterm use of inhaled corticosteroids on bone mineral density in asthmatic women, Respirology., 6, 131, 10.1046/j.1440-1843.2001.00323.x Israel, 2001, Effects of inhaled glucocorticoids on bone density in premenopausal women, N Engl J Med., 345, 941, 10.1056/NEJMoa002304 Kelly, 2003, Growth and bone density in children with mild-moderate asthma: A crosssectional study in children entering the Childhood Asthma Management Program (CAMP), J Pediatr., 142, 286, 10.1067/mpd.2003.86 Harmanci, 2001, Fluticasone propionate and budesonide do not influence bone metabolism in the long-term treatment of asthma, Allergol Immunopathol (Madr)., 29, 22, 10.1016/S0301-0546(01)79011-8 Sharma, 2003, Effect of inhaled steroids on bone mineral density: A meta analysis, J Clin Pharmacol., 43, 193, 10.1177/0091270002239829 Tattersfield, 2001, Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years, Thorax, 56, 272, 10.1136/thorax.56.4.272 Li, 1999, Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2years in adults with mild asthma, J Allerg Clin Immunol., 103, 1062, 10.1016/S0091-6749(99)70180-6 Kemp, 2004, Potential effects of fluticasone propionate on bone mineral density in patients with asthma: A 2-year randomized, double-blind, placebocontrolledtrial, 79, 458 Hubbard, 2002, Inhaled corticosteroids and hip fracture: A population-based case control study, Am J Respir Crit Care Med., 166, 1563, 10.1164/rccm.200206-606OC Suissa, 2004, Inhaled and nasal corticosteroid use and the risk of fracture, Am J Respir Crit Care Med., 169, 83, 10.1164/rccm.200305-640OC Dreyer, 1993, Inhaled steroid use and glaucoma, N Engl J Med., 329, 1822, 10.1056/NEJM199312093292420 Garbe, 1997, Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma, JAMA, 277, 722, 10.1001/jama.277.9.722 Mitchell, 1999, Inhaled corticosteroids, family history, and risk of glaucoma, Ophthalmology, 106, 2301, 10.1016/S0161-6420(99)90530-4 Opatowsky, 1995, Intraocular pressure elevation associated with inhalation and nasal corticosteroids, Ophthalmology, 102, 177, 10.1016/S0161-6420(95)31039-1 Cumming, 1997, Use of inhaled corticosteroids and the risk of cataracts, N Engl J Med., 337, 8, 10.1056/NEJM199707033370102 Pick, 2001, The risk of cataract among users of inhaled steroids, Epidemiology, 12, 229, 10.1097/00001648-200103000-00016 Smeeth, 2003, A population based case-control study of cataract and inhaled corticosteroids, BrJOphthalmol, 87, 1247 Toogood, 1993, Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment ofasthma, J Allery Clin Immunol, 91, 571, 10.1016/0091-6749(93)90263-F Simons, 1993, Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids, Lancet, 342, 776, 10.1016/0140-6736(93)91541-S Autio, 1996, Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo, Am J Respir Crit Care Med., 153, 1172, 10.1164/ajrccm.153.3.8630563 Capewell, 1990, Purpura and dermal thinning associated with high dose inhaled corticosteroids, BMJ, 300, 1548, 10.1136/bmj.300.6739.1548 Storms, 1998, Clinical adverse effects of inhaled corticosteroids: Results of a questionnaire survey of asthma specialists, Ann Allergy Asthma Immunol, 80, 391, 10.1016/S1081-1206(10)62989-4 Lipworth, 2000, Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium, Drug Saf, 23, 11, 10.2165/00002018-200023010-00002 Edsbacker, 1999, Pharmacological factors that influence the choice of inhaled corticosteroids, Drugs, 58, 7, 10.2165/00003495-199958004-00002 Rohatagi, 1996, Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate, J Clin Pharmacol., 36, 938, 10.1002/j.1552-4604.1996.tb04761.x Mackie, 2000, Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant, Clin Pharmacokinet., 39, 17, 10.2165/00003088-200039001-00003 Lyttle, 2003, Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children, Can Respir J., 10, 103, 10.1155/2003/627531 Asmus, 2002, In vitro deposition of fluticasone aerosol from a metered-dose inhaler with and without two common valved holding chambers, Ann Allergy Asthma Immunol., 88, 204, 10.1016/S1081-1206(10)61997-7 Cripps, 2000, Pharmaceutical transition to non-CFC pressurized metered dose inhalers, Respir Med., 94, S3, 10.1016/S0954-6111(00)80143-2 Leach, 2002, Lung deposition of hydrofluoroalkane-134a beclo methasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbonbeclomethasone: A cross-over study in healthy volunteers, Chest, 122, 510, 10.1378/chest.122.2.510 Kaliner, 2003, The receptor binding of ciclesonide: Comparison to other inhaled corticosteroids, Ann Allergy Asthma Immunol., 90, 129 Rohatagi, 2003, PK/PD of inhaled corticosteroids: The risk/benefit of ciclesonide, J Allergy Clin Immunol, 111, A598, 10.1016/S0091-6749(03)80757-1 Leach CL, Bethke TD, Boudreau RJ,et al.2-D and 3-D imaging show ciclesonide has high lung deposition and peripheral distribution: A nonrandomized study in healthy volunteers. J Aerosol Med. In press. Rohatagi, 2005, Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide, Am J Ther., 12, 201 Nave, 2004, Pharmacokinetics of [14C] ciclesonide after oral and intravenous administration to healthy subjects, Clin Pharmacokinet., 43, 479, 10.2165/00003088-200443070-00004 Miller-Larsson, 2003, Relative lipophilicity of budesonide, fluticasone propionate, mometasone furoate, and ciclesonide. Prevalence of variable lipophilicity in airways versus systemic compartments, Am J RespirCrit Care Med., 167, A773 2003 National Asthma Education and Prevention Program, 2002 Lipworth, 1999, Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta analysis, Arch Intern Med., 159, 941, 10.1001/archinte.159.9.941 Szefler, 2002, Significant variability in response to inhaled corticosteroids for persistent asthma, J Allergy Clin Immunol., 109, 410, 10.1067/mai.2002.122635 Boorsma, 1996, Assessment of the relative systemic potency of inhaled flu ticasone and budesonide, Eur Respir J., 9, 1427, 10.1183/09031936.96.09071427 Brus, 1999, Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults, Arch Intern Med., 159, 1903, 10.1001/archinte.159.16.1903 Casale, 2001, Suppression of hypothalamicpituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients, Ann Allergy Asthma Immunol., 87, 379, 10.1016/S1081-1206(10)62918-3 Clark, 1997, Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients, Thorax, 52, 55, 10.1136/thx.52.1.55 Fowler, 2001, Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate, Br J Clin Pharmacol., 52, 93, 10.1046/j.0306-5251.2001.bjcp.1399.x Fowler, 2002, Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate, Chest, 122, 618, 10.1378/chest.122.2.618 Martin, 2002, Systemic effect comparisons of six inhaled corticosteroid preparations, Am J Respir Crit Care Med., 165, 1377, 10.1164/rccm.2105013 Jarvis, 1999, Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma, Drugs, 57, 769, 10.2165/00003495-199957050-00016 Chervinsky, 1994, Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma, J Allergy Clin Immunol, 94, 676, 10.1016/0091-6749(94)90174-0 Weiner, 1999, Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate, Chest, 116, 931, 10.1378/chest.116.4.931 White M, Crisalida T, Li H, et al. Effects of long term inhaled corticosteroids on adrenal function in asthmatics. Ann Allergy Asthma Immunol. In press. Wong, 2002, Estimation of the dose of fluticasone propionate inhaled by infants after bronchiolitis: Effect on urinary cortisol excretion, J Allergy Clin Immunol, 110, 721, 10.1067/mai.2002.128858 Eid, 2002, Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate, Pediatrics, 109, 217, 10.1542/peds.109.2.217 Kannisto, 2002, Biochemical markers of bone metabolism in relation to adrenocortical and growth suppression during the initiation phase of inhaled steroid therapy, Pediatr Res, 52, 258, 10.1203/00006450-200208000-00019 Wong, 2002, Growth and adrenal suppression in asthmatic children on moderate to high doses offluticasone propionate, J Paediatr Child Health, 38, 59, 10.1046/j.1440-1754.2002.00717.x Griffiths, 2004, Effect of high-dose fluticasone propionate on bone density and metab olism in children with asthma, Pediatr Pulmonol, 37, 116, 10.1002/ppul.10396 De Swert, 2004, Myopathy in children receiving highdose inhaled fluticasone, N Engl J Med., 350, 1157, 10.1056/NEJM200403113501122 Bundschuh, 2001, Efficacy and safety profile of the novel on-site activated corticosteroid ciclesonide, Am J Respir Crit Care Med, 163, A588 Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in the human lung and liver precision-cut tissue slices. Biopharm Drug Dispos. In press. Rohatagi, 2003, Population pharmacokinetics and pharmacodynamics of ciclesonide, J Clin Pharmacol, 43, 365, 10.1177/0091270002250998 Vanden Burgt, 2000, Efficacy and safety overview of new inhaled cortico steroid, QVAR (hydrofluoroalkanebeclomethasone extrafine inhalation aerosol), in asthma, J Allergy Clin lmmunol, 106, 1209, 10.1067/mai.2000.111582 Richter, 2005, Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma, J Gin Pharmacol., 45, 146 Banerji, 2004, Ciclesonide and placebo have similar incidence of oropharyngeal ad verse events in adolescent/adult and pediatric asthma patients: Results frompooled analyses, 25, P206 Pearlman, 2005, Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma, J Allergy Clin Immunol., 116, 1206, 10.1016/j.jaci.2005.08.037 Bernstein, 2004, Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma, J Allergy Clin Immunol, 113, A349 Lipworth, 2005, Effect of ciclesonide and fluticasone on hypothalamic-pituitaryadrenal axis function in adults with mild-to-moderate persistent asthma, Ann Allergy Asthma Immunol, 94, 465, 10.1016/S1081-1206(10)61117-9 Chapman, 2005, Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma, Allergy, 60, 330, 10.1111/j.1398-9995.2004.00750.x Nave, 2005, Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide, Pulm Pharmacol Ther., 18, 390, 10.1016/j.pupt.2005.02.012 Peet, 2005, Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes, Eur J Drug Metab Pharmacokinet, 30, 275, 10.1007/BF03190632 Postma, 2001, Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening, Eur Respir J., 17, 1083, 10.1183/09031936.01.00099701 Chapman, 2002, Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study, Eur Respir J., 20, S373 Derom, 2005, Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′ monophosphate in asthmatic patients, Pulm Pharmacol Ther., 18, 328, 10.1016/j.pupt.2005.01.004 Szefler, 2005, Ciclesonide, a novel inhaled steroid, does not affect hypothalamic pituitary-ad renal axis functionin patients with moderate-to-severe persistentasthma, Chest, 128, 104, 10.1378/chest.128.3.1104 Weinbrenner, 2002, Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide, J Clin Endocrinol Metab., 87, 2160, 10.1210/jc.87.5.2160 O'Connor, 2002, Management of moderate to severe bronchial asthma by cicle sonide: A 12-week trial, Am J Respir Crit Care Med., 165, A767 O'Connor, 2002, Treatment of moderate to severe asthma with ciclesonide: A long-term investigation over 52 weeks, Eur Respir J., 20, S406